Want to see GB:PYC full AI Analyst Report?
PYC Stock Chart & Stats
0.28 p
0.05 p(6.45%)
At close: 4:00 PM EST
0.28 p
0.05 p(6.45%)
Day’s Range― - ―
52-Week Range0.25 p - 0.80 p
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.43M
Market Cap
£2.49M
Enterprise Value1.34M
Total Cash (Recent Filing)£257.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~51% revenue rebound in 2025 indicates durable demand for Physiomics' services and validates its market fit. Sustained top-line recovery can expand the client pipeline, enable operating leverage as fixed costs are absorbed, and materially improve the runway toward profitability if maintained.
Balance Sheet HealthEssentially zero debt provides structural financial flexibility and lowers refinancing risk. A low-leverage balance sheet allows management to prioritize reinvestment in sales and product capabilities or pursue non-dilutive partnerships, giving the company runway to address operating losses over the medium term.
Specialized Business ModelA focused, technical service offering in oncology modelling creates high entry barriers and sticky client relationships. Proprietary expertise and project-driven engagements with biopharma produce repeatable fee-for-service revenue and position the firm to benefit from structural industry demand for translational modelling.
Bears Say
Cash BurnSustained negative operating and free cash flow (~-£0.55M) is a structural weakness that necessitates external financing or dilutive raises over time. Persistent cash outflows constrain investments in business development, hiring, and product enhancement, increasing execution and funding risk if growth slows.
Persistent Losses And MarginsThe company remains loss-making despite revenue gains, reflecting weak margin conversion. Continued inability to turn revenue into sustainable profits undermines self-funding, limits reinvestment capacity, and prolongs dependence on external capital, delaying a durable path to positive earnings.
Negative Returns / Dilution RiskA ROE near -60% shows shareholder capital is being eroded by losses. Persistently negative returns raise the likelihood of equity issuance or costly financing, which would dilute existing holders and restrict strategic options, representing a structural governance and capital-allocation concern.
Physiomics News
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.25 p and its highest was 0.80 p in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is £2.49M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 69 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.